Work

CGRP and Migraine: Real-World Insights and Future Therapeutic Directions

Year: 2025

Type: review

Abstract: Therapeutic targeting of the neuropeptide calcitonin gene-related peptide (CGRP) is a bench-to-bedside success story that has established migraine as a treatable neurological disorder. There are now eight monoclonal antibodies and small-molecule receptor antagonists approved by the US Food and Drug Administration for the acute and preventive treatment of migraine. This review focuses on evolving real-world data for these inhibitors of CGRP activity. While the drugs have been remarkably safe so far, some adverse effects are arising. To conclude, we speculate on the emerging use of CGRP inhibitors for other disorders and what lies on the horizon for combinatorial and neuropeptide-based treatments inspired by the CGRP story.

Source: Annual Review of Medicine

DOI: 10.1146/annurev-med-050224-111631

Authors: Andrew F. Russo, Eric A. Kaiser

Institutions: University of Iowa, Iowa City VA Health Care System, University of Pennsylvania

Language: English

Topic: Migraine and Headache Studies

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: National Institutes of Health, National Institute of Neurological Disorders and Stroke